
Experts at AMCP Nexus 2026 said payers are using maximum fair prices (MFPs) as leverage while manufacturers rethink rebate and evidence strategies.

Hiva Pourarsalan, PharmD, is director of pharmacy at Aetna.

Experts at AMCP Nexus 2026 said payers are using maximum fair prices (MFPs) as leverage while manufacturers rethink rebate and evidence strategies.

Maximum Fair Prices are reshaping Part D formularies, with plans favoring lower net-cost options, panelists said at AMCP Nexus 2026.

A small expert panel was selected to share professional experiences with risk-sharing agreements and advance the cost-effective utilization of continuous glucose monitoring–centered care in type 2 diabetes (T2D).

November 3rd 2026